

1645



Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<h1>TRANSMITTAL FORM</h1> <p>(to be used for all correspondence after initial filing)</p>	Application Number	09/896,186	
	Filing Date	June 29, 2001	
	First Named Inventor	Levin	
	Group Art Unit	1645	
	Examiner Name	Not Yet Assigned	
Total Number of Pages in This Submission		4	
		Attorney Docket Number	PB/5-31481A

RECEIVE

JAN 28 2002

TECH CENTER 1600/

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Reply (Second Preliminary) <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Mary Kakefuda, Reg. No. 39,245 Syngenta Biotechnology, Inc.
Signature	<i>Mary Kakefuda</i>
Date	10/22/01

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: 10/22/2001			
Typed or printed name	Melissa Hardy	Date	10/22/2001
Signature	<i>Melissa Hardy</i>		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



**CERTIFICATE OF MAILING**

hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Box: Non-Fee Amendment, Commissioner for Patents, Washington, D.C. 20231.

Melissa Hardy  
Type or print name

*Melissa Hardy*  
Signature

October 22, 2001  
Date

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**RECEIVED**

JAN 28 2002

TECH CENTER 1600/290

IN RE APPLICATION OF

LEVIN ET AL.

APPLICATION NO.: 09/896,186

FILED: June 29, 2001

FOR: Methods of Controlling Gene Expression  
and Gene Silencing

ART UNIT: 1645

CONFIRMATION NO.: 9567

DOCKET: PB/5-31481A

**SECOND PRELIMINARY AMENDMENT UNDER 37 C.F.R. §1.111**

Box: Non-Fee Amendment  
Commissioner for Patents  
Washington, D.C. 20231

Sir:

Prior to examination of the above-identified patent application, please enter the following amendments and consider the remarks below.

**IN THE SPECIFICATION:**

Please amend the specification to read as follows:

On page 52, Example 5:

--The line 8Z-2 (see Example 4 above) is crossed with the line S11.13-34 (see Example 2 above) and the resultant F1 generation plants are allowed to self-fertilize to obtain the F2 generation. Approximately 60 F2 plants are grown and tested for a presence of T-DNA insertion in the RDRD gene derived from the S11.13-34 parental line and for the 35S-GFP T-DNA derived from the 8Z-2 parental line. The presence of the T-DNA insertion in the RDRD gene is demonstrated as described in Example 2. Plants carrying this T-DNA insertion are then checked for homozygosity by PCR using the 3' specific primer (SEQ ID NO:19) and 36851TD#3 (5'-gct ccg ccc aca taa ttc aaa caa cac-3', SEQ ID NO:29). These primers span a region of genomic DNA including the insertion site such that only the wild-type copy of DNA results in

A<sup>1</sup>